John Hussman's NVO Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 42.0K shares of Novo Nordisk A/S (NVO) worth $2.33 M, representing 0.50% of the portfolio. First purchased in 2024-Q1, this short-term holding has been held for 7 quarters.
Based on 13F filings, John Hussman has maintained this position in NVO for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2024, adding 12.6K shares. Largest reduction occurred in Q2 2025, reducing 10.5K shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Novo Nordisk A/S (NVO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Novo Nordisk A/S (NVO) Trades by John Hussman
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2024 | +31,500 | New Buy | 31,500 | $128.40 |
| Q2 2024 | +10,500 | Add 33.33% | 42,000 | $142.74 |
| Q3 2024 | +8,400 | Add 20.00% | 50,400 | $119.07 |
| Q4 2024 | +12,600 | Add 25.00% | 63,000 | $86.02 |
| Q2 2025 | -10,500 | Reduce 16.67% | 52,500 | $69.02 |
| Q3 2025 | -10,500 | Reduce 20.00% | 42,000 | $55.49 |
John Hussman's Novo Nordisk A/S Investment FAQs
John Hussman first purchased Novo Nordisk A/S (NVO) in Q1 2024, acquiring 31,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Novo Nordisk A/S (NVO) for 7 quarters since Q1 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's largest addition to Novo Nordisk A/S (NVO) was in Q1 2024, adding 31,500 shares worth $4.04 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 42,000 shares of Novo Nordisk A/S (NVO), valued at approximately $2.33 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Novo Nordisk A/S (NVO) represents approximately 0.50% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's peak holding in Novo Nordisk A/S (NVO) was 63,000 shares, as reported at the end of Q4 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.